arrow
W

Wesley Yip

city of hope comprehensive cancer center
H指数:14
被引数:575

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis

局部前列腺癌行根治性前列腺切除术的拉丁裔亚人群结局差异:一项基于人群的分析

Cancers
IF4.4
2026-04-030
OAAI
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

肌层浸润性膀胱癌患者根治性膀胱切除术中病理疾病升级的临床预测因素及预后意义

2025-10-090
OA
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体药物偶联物联合疗法在晚期尿路上皮癌中的疗效与安全性

2025-10-070
OAAI
VHL and TP53 mutation status are not associated with response or progression-free survival in metastatic renal cell carcinoma treated with VEGF-targeted therapies

VHL和TP53突变状态与接受VEGF靶向治疗的转移性肾细胞癌的治疗反应或无进展生存期无关。

2025-10-010
OAAI
Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials

真实世界证据表明,在乳头状肾细胞癌中,当代一线策略并未显示出生存优势:呼吁开展随机试验

2025-10-010
OA
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

临床和病理学预测因子:在接受根治性膀胱切除术的临床淋巴结阴性的膀胱癌患者中 occult 淋巴结受累的预测因子

2025-09-010
PRE
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

分子异质性和免疫浸润驱动上尿路尿路上皮癌的临床结局

2025-03-011
OAAI
Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study

免疫检查点抑制剂治疗后肾切除术的围手术期并发症和肿瘤学结局: 一项多中心合作研究

2023-12-017
PRE